Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    Pregnancy and Neonatal Outcomes in SARS-CoV-2 Infection MESHD: a systematic review

    Authors: Reem S Chamseddine; Farah Wahbeh; Frank Chervenak; Laurent J Salomon; Baderledeen Ahmed; Arash Rafii

    doi:10.1101/2020.05.11.20098368 Date: 2020-05-18 Source: medRxiv

    With the emergence of SARS-CoV-2 and its rapid spread, concerns regarding its effects on pregnancy outcomes have been growing. We reviewed 164 pregnancies complicated by maternal SARS-CoV-2 infection MESHD across 20 studies. The most common clinical presentations were fever HP fever MESHD (57.9%), cough HP (35.4%), fatigue HP fatigue MESHD (15.2%), and dyspnea HP dyspnea MESHD (12.2%). Only 2.4% of patients developed respiratory distress HP. Of all patients, 84.5% delivered via Cesarean section, with a 23.9% rate of maternal gestational complications, 20.3% rate of preterm delivery, and a concerning 2.3% rate of stillbirth delivery MESHD. Relative to known viral infections, the prognosis for pregnant women with SARS-CoV-2 is good, even in the absence of specific antiviral treatment. However, neonates and acute patients, especially those with gestational or pre-existing co-morbidities, must be actively managed to prevent severe outcomes.

    Clinical Manifestation and Maternal Complications and Neonatal outcomes in Pregnant Women with COVID 19: An Update a Systematic Review and Meta-analysis

    Authors: Marzieh Soheili; Ghobad Moradi; Hamid Reza Baradaran; Maryam Soheili; Yousef Moradi

    doi:10.21203/rs.3.rs-27383/v1 Date: 2020-05-07 Source: ResearchSquare

    Background Existing evidence indicates that the risk of obstetric and perinatal outcomes is higher in women with coronavirus infection MESHD. outbreaks suggest that pregnant women and their fetuses are particularly susceptible to poor outcomes. However, there is little known about pregnancy related complications and co-morbidity in this group of women. Therefore, this, systematic review and meta-analysis performed in order to find out whether COVID-19 may cause different manifestations and outcomes in antepartum and postpartum period or not.Methods We searched databases, including Medline (PubMed), Embase, Scopus, Web of sciences, Cochrane library, Ovid and CINHAL to retrieve all articles reporting the prevalence SERO of maternal and neonatal complications, in addition clinical manifestations, in pregnant women with COVID 19 that published with English language from January to April 2020. Results 11 studies with total 177 pregnant women included in this systematic review.Results show that the pooled prevalence SERO of neonatal mortality, lower birth weight, stillbirth MESHD, premature birth HP, and intrauterine fetal distress MESHD fetal distress HP in women with COVID 19 were 4% (95% Cl: 1 - 9%), 21% (95% Cl: 11 – 31%), 2% (95% Cl: 1 - 6%), 28% (95% Cl: 12 - 44%), and 15% (95% Cl: 4 - 26%); respectively. Also the pooled prevalence SERO of fever HP fever MESHD, cough HP cough MESHD, diarrhea HP diarrhea MESHD and dyspnea HP dyspnea MESHD were 56% (95% Cl: 30 - 83%), 30% (95% Cl: 21 - 39%), 9% (95% Cl: 2 - 16%), and 3% (95% Cl: 1 - 6%) in the pregnant women with COVID-19.Conclusion According to this systematic review and meta-analysis, the pregnant women with COVID-19 with or without pneumonia HP pneumonia MESHD, are at a higher risk of pre- eclampsia HP eclampsia MESHD, preterm birth, miscarriage and cesarean delivery. Furthermore, the risk of LBW and intrauterine fetal distress HP seems increased in neonates.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.